Delving into the Latest Updates on Desoximetasone with Synapse

Psoriasis and atopic dermatitis are chronic inflammatory disease that account for a significant amount of patients in most dermatological practices. Topical corticosteroid agents are often prescribed for treatment of both these conditions, especially when they are localized rather than wide spread. The development of resistance to treatment is termed tachyphylaxis. Poor adherence, rather than down regulation of receptors, may be the primary cause of tachyphylaxis to topical corticosteroids. The primary objective of the study is to determine, under conditions designed to assure good adherence, whether topical 0.25% desoximetasone spray improves clinical outcomes in patients who have resistant inflammatory skin disease defined by failure of previous topical steroid treatment.

Start Date01 Feb 2017

Sponsor / Collaborator

Wake Forest School of Medicine

NCT02932878 / CompletedPhase 2

An Open Label, Safety Study to Assess the Potential for Adrenal Suppression Following Treatment With DSXS Topical Product in Patients With Plaque Psoriasis

An Open Label, Safety Study to Assess the Potential for Adrenal Suppression Following Treatment with DSXS (Taro Pharmaceuticals U.S.A., Inc.) in Patients with Plaque Psoriasis

Start Date02 Sep 2016

Sponsor / Collaborator

Taro Pharmaceuticals U.S.A., Inc.

NCT02985736 / CompletedPhase 4IIT

An Open-Label, Study Evaluating Topicort® Topical Spray 0.25% (Desoximetasone) in Patients With Scalp Psoriasis

A single center, study of 20 subjects to assess 4 weeks of therapy with Topicort® twice daily BID and 12 weeks twice daily on 2 consecutive days to patients with scalp psoriasis

Start Date01 Sep 2016

Sponsor / Collaborator

Taro Pharmaceuticals U.S.A., Inc.

100 Clinical Results associated with Desoximetasone

Login to view more data

100 Translational Medicine associated with Desoximetasone

Login to view more data

100 Patents (Medical) associated with Desoximetasone

Login to view more data

121

Literatures (Medical) associated with Desoximetasone

01 Nov 2023·Analytical and bioanalytical chemistry

Improved analysis of derivatized steroid hormone isomers using ion mobility-mass spectrometry (IM-MS).

Article

Author: Lucas, Shadrack Wilson ; Neal, Shon P ; Velosa, Diana C ; Aderorho, Ralph ; Chouinard, Christopher D ; Hodges, Walker N

Over the last decade, applications of ion mobility-mass spectrometry (IM-MS) have exploded due primarily to the widespread commercialization of robust instrumentation from several vendors. Unfortunately, the modest resolving power of many of these platforms (~40-60) has precluded routine separation of constitutional and stereochemical isomers. While instrumentation advances have pushed resolving power to >150 in some cases, chemical approaches offer an alternative for increasing resolution with existing IM-MS instrumentation. Herein we explore the utility of two reactions, derivatization by Girard's reagents and 1,1-carbonyldiimidazole (CDI), for improving IM separation of steroid hormone isomers. These reactions are fast (≤30 min), simple (requiring only basic lab equipment/expertise), and low-cost. Notably, these reactions are structurally selective in that they target carbonyl and hydroxyl groups, respectively, which are found in all naturally occurring steroids. Many steroid hormone isomers differ only in the number, location, and/or stereochemistry of these functional groups, allowing these reactions to "amplify" subtle structural differences and improve IM resolution. Our results show that resolution was significantly improved amongst CDI-derivatized isomer groups of hydroxyprogesterone (two-peak resolution of R_pp = 1.10 between 21-OHP and 11B-OHP), deoxycortisone (R_pp = 1.47 between 11-DHC and 21-DOC), and desoximetasone (R_pp = 1.98 between desoximetasone and fluocortolone). Moreover, characteristic collision cross section (^DTCCS_N2) measurements can be used to increase confidence in the identification of these compounds in complex biological mixtures. To demonstrate the feasibility of analyzing the derivatized steroids in complex biological matrixes, the reactions were performed following steroid extraction from urine and yielded similar results. Additionally, we applied a software-based approach (high-resolution demultiplexing) that further improved the resolving power (>150). Overall, our results suggest that targeted derivatization reactions coupled with IM-MS can significantly improve the resolution of challenging isomer groups, allowing for more accurate and efficient analysis of complex mixtures.

25 Jul 2023·Pharmaceutics

A Promising Approach to Treat Psoriasis: Inhibiting Cytochrome P450 3A4 Metabolism to Enhance Desoximetasone Therapy.

Article

Author: Lim, Cherng-Jyr ; Jee, Shiou-Hwa ; Liu, Chih-Yi ; Guo, Jiun-Wen ; Cheng, Yu-Pin

(1) Background: Human keratinocytes and murine skin express various cytochrome P450 enzymes. These include cytochrome P450 3A4, which may participate in the metabolism of cytochrome P450 3A4 substrate drugs. Desoximetasone, a topical corticosteroid and cytochrome P450 3A4 substrate, is used to treat skin conditions such as skin allergies, atopic dermatitis, and psoriasis. In this study, we aimed to investigate the anti-psoriatic effect of a low dose of desoximetasone by inhibiting cytochrome P450 3A4 metabolism in the epidermis. (2) Methods: Psoriasis-like skin was induced in BALB/c mice via the topical administration of imiquimod. The mice were then topically treated with 0.01-0.05% desoximetasone loaded into a cytochrome P450 3A4 enzyme inhibitor excipient base emollient microemulsion, 0.25% commercial desoximetasone ointment, or 0.5 mg/gm clobetasol ointment. (3) Results: The topical application of 0.05% desoximetasone loaded into a cytochrome P450 3A4 enzyme inhibitor excipient base emollient formulation restored the imiquimod-induced skin barrier disruption and resulted in fewer severe clinical and pathological features compared with the treatments with 0.25% commercial desoximetasone ointment and 0.5 mg/gm clobetasol ointment. (4) Conclusions: The cytochrome P450 3A4 enzyme inhibitor excipient base emollient formulation improved and prolonged the therapeutic effect of cytochrome P450 3A4 substrate drugs and may be a promising approach for psoriasis treatment.

01 Jun 2023·Contact Dermatitis

Airborne and systemic allergic contact dermatitis due to corticosteroids

Author: Vico, Francesca Di ; Potestio, Luca ; Patruno, Cataldo ; Fabbrocini, Gabriella ; Napolitano, Maddalena

This study is on the airborne and systemic allergic contact dermatitis due to corticosteroids.A 37-yr-old female developed an edematous dermatitis of the face about 6h after she had held her daughter in her arms while the child was aerosoled for asthma with a medication (Aircort solution, Italchimici, Italy) containing budesonide 1 mg, sodium citrate, sodium chloride, disodium edetate, anhydrous citric acid, polysorbate 80, and water for injections.Patch testing with corticosteroid series (desoximetasone 0.1% pet, betamethasone 17-valerate 0.1% pet, hydrocortisone 17-butyrate 0.1% pet) (FIRMA, Florence, Italy) resulted in a pos. reaction to hydrocortisone 17-butyrate 0.1% pet (++at D3, D4, and D7).These patch test results are consistent with the diagnosis of airborne allergic contact dermatitis (ACD) 'by proxy' caused by aerosoled budesonide followed by systemic contact dermatitis due to prednisone.

100 Deals associated with Desoximetasone

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D03697	Desoximetasone	D07AC03 D07XC02	DB00547

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Plaque psoriasis	US	Taro Pharmaceuticals, Inc.	11 Apr 2013
Dermatophilosis	US	Taro Pharmaceutical Industries Ltd.	17 Jan 1985

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Psoriasis of scalp	Preclinical	US	Taro Pharmaceuticals U.S.A., Inc.	11 Jul 2016
Scalp Dermatoses	Preclinical	US	Taro Pharmaceuticals U.S.A., Inc.	11 Mar 2016
Moderate Atopic Dermatitis	Preclinical	US	Taro Pharmaceuticals U.S.A., Inc.	04 Sep 2015
Severe Atopic Dermatitis	Preclinical	US	Taro Pharmaceuticals U.S.A., Inc.	04 Sep 2015
Plaque psoriasis	Preclinical	-	Taro Pharmaceuticals U.S.A., Inc.	01 Aug 2010

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02985736 (CTgov)	Phase 4	Psoriasis of scalp	20	Topicort	mtlppjadol(kabrmlwnpc) = pcfgqondxb zvmhwxvhlt (nciogeriyv, jemzucwbww - vfmvcexpob) View more	-	09 Apr 2024
NCT02618759 (CTgov)	Phase 3	Plaque psoriasis	119	Placebo+DSXS (DSXS1505)	kjlcalfblu(mwtvbnlfcy) = uzfazzemju pbxhasitar (mynhsinaub, yzrpchwnwq - jagpcnspji) View more	-	10 Dec 2018
				Placebo+DSXS (Placebo)	kjlcalfblu(mwtvbnlfcy) = dwhwlbuzke pbxhasitar (mynhsinaub, hvucxprmkc - zjluiyswzm) View more
NCT02595073 (CTgov)	Phase 3	Moderate Atopic Dermatitis \| Severe Atopic Dermatitis	124	DSXS (DSXS Topical Product)	svoildbriv(yjistvsqvl) = lrltsczyax huseiwzkjl (vgzispexei, erdysxzkco - ztmvjaoypo) View more	-	07 Dec 2018
				Placebo (Placebo Topical Product)	svoildbriv(yjistvsqvl) = yjrsapwofe huseiwzkjl (vgzispexei, bxxxtxwurg - njwppqlgyl) View more
NCT02601469 (CTgov)	Phase 2	Plaque psoriasis	26	DSXS (DSXS1503 Cohort 1)	hbosexnyma(rbudwlcabu) = mbabomuxwe nwauiqwjmo (bujnqtayty, ptfargdfwt - llrykixtjc) View more	-	07 Dec 2018
				DSXS (DSXS1503 Cohort 2)	hbosexnyma(rbudwlcabu) = xjprqwzsdh nwauiqwjmo (bujnqtayty, hcalqrgsqs - fvhbbgmeok) View more
NCT02595008 (CTgov)	Phase 2	Dermatitis, Atopic	24	DSXS (DSXS Topical Product Cohort 1)	lyioardcop(flgkymwcnr) = pppmygrzkp jjxpqhwotr (kditnyltqp, jcqnzklnhf - lefwclefhw) View more	-	07 Dec 2018
				DSXS (DSXS Topical Product Cohort 2)	lyioardcop(flgkymwcnr) = uhonmlrknr jjxpqhwotr (kditnyltqp, dmqwuaejvq - xezwejrtmd) View more
NCT02932891 (CTgov)	Phase 2	Dermatitis, Atopic	28	DSXS	qwuohnnlzh(voayojzwvi) = eqydwdcdyn ouuaiylysp (cvzyfojmze, inznoruzqw - humxbmgpte) View more	-	07 Dec 2018
NCT02933528 (CTgov)	Phase 2	Psoriasis of scalp	24	DSXS Topical product	nprvtujdwv(gdyrwfqjch) = lygllxtuek wfepdqmznf (vubygankvh, hjyuloqzyq - aeypyxsjys) View more	-	06 Dec 2018
NCT02933866 (CTgov)	Phase 3	Scalp Dermatoses	371	DSXS topical (DSXS Topical)	badisctwdl(lvuqciqkec) = aoobdbbfgf ojsfbqurrm (gbmicfszay, vdldnhozae - ksjpbijuxg) View more	-	06 Dec 2018
				Vehicle topical (Vehicle Topical)	badisctwdl(lvuqciqkec) = sgvgrhjiun ojsfbqurrm (gbmicfszay, nnrdgurius - fwqoclcutq) View more
NCT02932878 (CTgov)	Phase 2	Plaque psoriasis	16	DSXS (DSXS Topical Cohort 1)	ckweraxuvs(dehozgvwaw) = qvtfsrbmqw dceazrlgmn (rrzitmhafh, rpyxgrchxo - wyntxbfkqs) View more	-	06 Dec 2018
				DSXS (DSXS Topical Cohort 2)	ckweraxuvs(dehozgvwaw) = njhhfclufg dceazrlgmn (rrzitmhafh, pfvrfjfriz - kfrxtjsidp) View more
NCT03050294 (CTgov)	Phase 4	Psoriasis \| Dermatitis, Atopic	24	Desoximetasone 0.25% spray (Control- Atopic Dermatitis)	jkzrahynhi(yusdzaywcq) = gbymdskuqh byklfmrluf (sfnpafqtex, dqnzfulcjj - ljnpczmgcg) View more	-	15 Jun 2018
				Phone calls+Desoximetasone 0.25% spray (Atopic Dermatitis Intervention)	jkzrahynhi(yusdzaywcq) = cynkgdwxmf byklfmrluf (sfnpafqtex, imxqbmjbal - lhjhmfcdbw) View more